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ABSTRACT
DNA replication initiation is a key event in the cell cycle, which is dependent on 2 kinases - CDK2 and
CDC7. Here we report a novel mechanism in which p53 induces G1 checkpoint and cell cycle arrest by
downregulating CDC7 kinase in response to genotoxic stress. We demonstrate that p53 controls CDC7
stability post-transcriptionally via miR-192/215 and post-translationally via Fbxw7b E3 ubiquitin ligase. The
p53-dependent pathway of CDC7 downregulation is interlinked with the p53-p21-CDK2 pathway, as p21-
mediated inhibition of CDK2-dependent phosphorylation of CDC7 on Thr376 is required for GSK3ß-
phosphorylation and Fbxw7ß-dependent degradation of CDC7. Notably, sustained oncogenic high levels
of active CDC7 exert a negative feedback onto p53, leading to unrestrained S-phase progression and
accumulation of DNA damage. Thus, p53-dependent control of CDC7 levels is essential for blocking G1/S
cell-cycle transition upon genotoxic stress, thereby safeguarding the genome from instability and thus
representing a novel general stress response.
KEYWORDS
CDC7; CDK2; cell cycle; DNA
damage; DNA replication;
Fbxw7b; GSK3b; miRNA-192/
215; p21; p53; protein
degradation
Introduction
The threat of genomic damage to the cell arises intrinsically
through errors during DNA replication, as well as through
genotoxic stress from reactive oxygen metabolites and exoge-
nous stimuli (e.g. ionising radiation, chemotherapy, ultraviolet
light). The p53 tumor suppressor protein maintains genomic
stability by arresting cell cycle progression following exposure
to genotoxic stimuli. p53 imposes either cell cycle arrest, which
prevents the replication of damaged DNA, or triggers
programmed cell death (apoptosis) which reduces the risk for
cell transformation.1-5 p53 executes its master regulation of cell
division via transcriptional, post-transcriptional and post-
translational mechanisms.6,7 A paradigm for cell cycle arrest in
response to DNA damage involves p21 (a transcriptional target
of p53), which blocks cell cycle progression through the inhibi-
tion of cyclin-dependent kinases (CDK2) and the DNA
polymerase d-processivity factor PCNA.8 In addition, p53-
dependent upregulation of micro-RNAs (mi-RNAs)9-11 such as
mi-R34a and mi-R34b/c represents a post-transcriptional
mechanism for regulation of gene expression.11-13 Fbxw7b, the
F-box recognition module of the Skp1-Cul1-Rbx1 E3 ubiquitin
ligase complex is also a target of p53, which can modulate
CDK2 activity through post-translational targeting of cyclin
E.14 Inhibition of CDK2 through different p53-mediated
mechanisms impacts on the Rb/E2F pathway, suppressing
transcription of E2F-dependent S-phase commitment genes
and therefore cell cycle progression.15
CDK2 is one of 2 critical kinases involved in the initiation of
DNA replication. CDK2 governs the regulation of pre-replica-
tion complex (pre-RC) assembly through CDC6 stability, and
activates replication origins through phosphorylation of MCM-
proteins and Sld2-TopBP1-Sld3.16,17 However, the ﬁring of the
replication origins is strictly dependent on concerted and non-
redundant MCM helicase activation in situ by both CDK2 and
CDC7 (cell division cycle 7),17 with the latter considered the
essential trigger.18 CDC7 is the catalytic subunit of Dbf4-
dependent kinase (DDK) and acts in concert with its regulatory
subunit ASK (a human homolog of yeast Dbf4).19 Notably
overexpression of CDC7 has been shown to correlate signiﬁ-
cantly with the malignant phenotypes of different tumors.20-22
Moreover, CDC7 overexpression in multiple tumor cell lines
and tumor specimens from the breast, ovary and lung appears
to be inversely correlated with loss of p53, implying a func-
tional connection between p53 and CDC7 kinase.23
p53 is a transcription factor, yet screening for p53-transcrip-
tional binding sites within the human genome failed to identify
CDC7 as a p53 transcriptional target.24 This implies that either
an indirect transcriptional response or an alternative
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mechanism is responsible for the apparent p53-dependent reg-
ulation of CDC7. Recently, p53- and DNA damage-dependent
miRNA-192/215 were implicated in targeting a battery of pro-
liferation-linked transcripts including CDC7.25,26 However, the
p53-dependent miRNA regulatory loop had only moderate
effects on the CDC7 transcript levels (30% reduction) com-
pared to transfection with speciﬁc CDC7 siRNAs.26 This indi-
cates that a miRNA-based mechanism alone does not explain
the inverse relationship between p53 and CDC7, pointing
toward a parallel, hitherto unknown, regulatory p53-dependent
pathway(s). Given the role of CDC7 as a master switch in DNA
replication initiation and the association of CDC7
overexpression and malignant tumor phenotypes, CDC7
regulation by p53 might present a pathway that cooperates
with p53-p21-CDK2 inhibition to prevent genomic instability.
In this study we discovered a new p53-dependent stress
pathway that regulates CDC7. We demonstrate that this cell
stress pathway functions through post-transcriptional and post-
translational regulatory mechanisms. Moreover, the post-transla-
tional regulation of CDC7 via proteolytic degradation appears to
be dependent on the p53-p21-CDK2 pathway. Furthermore, the
sustained high levels of active CDC7 exert negative feedback
onto p53, leading to unrestrained S-phase progression and
accumulation of DNA damage. Our ﬁndings highlight the
importance of p53-CDC7 cell stress response pathway for the
maintenance of genomic stability and the impact deregulation
of this pathway may have on tumourigenesis.
Results
Cell cycle arrest following DNA damage is dependent
on p53-mediated CDC7 protein loss
We ﬁrst tested whether CDC7 is targeted in response to DNA
damage. IMR90 ﬁbroblasts were released from serum starva-
tion, exposed to irradiation (IR) or Doxorubicin (Doxo),
treated with Aphidicolin, and released into a drug-free medium
(Fig. 1A and Fig. S1A). In total, 95% of the irradiated cells
remained in G1, while 43% of untreated cells progressed into
S-phase (Fig. S1B). Furthermore, the presence of gH2A.X foci,
the accumulation of Rad51 protein27 and the phosphorylation
of p53 at Ser15 after treatment with either IR or Doxo
conﬁrmed the activation of DNA damage-dependent pathways
(Fig. 1B and Fig. S1C and D), followed by a rise in p53 levels
(Fig. 1C and D, corresponding lanes 4 and 10). Importantly,
the rise in p53 levels was correlated with the down-regulation
of CDC7 protein levels in both the whole cell- and nuclear
extracts (Fig. 1C and D, corresponding lanes 4 and 10). The
purity and lack of cross contamination between the nuclear-
and cytoplasmic fractions was conﬁrmed by immunoblotting
(Fig. S1H).28 Furthermore, Aphidicolin treatment alone did not
alter p53 or CDC7 protein levels (Fig. S1E), indicating that
both the stabilization of p53 and downregulation of CDC7
resulted from IR or Doxo treatment.
To investigate whether the IR/Doxo-induced decrease in
CDC7 protein levels was p53-dependent, we knocked down p53
expression in IMR90 cells prior to IR/Doxo treatment (Fig. 1C
and D, corresponding lanes 9 and 12 and Fig. S1F and G). Immu-
noblotting analysis demonstrated that the depletion of p53
abrogated the IR/Doxo-induced down-regulation of CDC7
(Fig. 1C and D) and resulted in a signiﬁcant (21–25%) increase in
the number of cells in S-phase (Fig. 1E, vi and ix, compared to iv
and vii respectively), while the rise in CDC7 levels after silencing
of p53 or ectopic expression of CDC7WT in non-stressed cells led
to a further increase of the S phase cell population by~6% com-
pared to control cells (Fig. 1E, ii and iii compared to i).
Interestingly, when CDC7 protein levels were rescued by
exogenous expression of CDC7 (CDC7WT) in IR/Doxo-treated
cells then this resulted in a partial bypass of the cell cycle arrest
(Fig. 1e, v and viii compared to iv and vii), demonstrating that
the p53-mediated downregulation of CDC7 protein levels in
response to stress is an integral part of the G1 cell cycle arrest.
The relief of the G1 arrest upon ectopic expression of CDC7 in
Doxo-treated cells was linked to CDK2 activity, as witnessed by
a reduction in p21 levels and the recovery of CDK2 activity
(Fig. S2A and B).
p53-dependent miR-192/215 up-regulation contributes
to G1 arrest and suppression of CDC7 mRNA
We next investigated the mechanism of p53-dependent CDC7
down-regulation without employing DNA damage, thus avoid-
ing potential side effects. To that end we used low-dose Actino-
mycin D (ActD) treatment, which results in highly speciﬁc
activation of p53.29 Immunoblotting analysis conﬁrmed p53
activation in ActD-treated IMR90 cells, and in keeping with
our previous results, showed an inverse correlation with CDC7
protein levels and a reduction in the number of cells in S-phase
compared with control cells (Fig. 2A and B). Depletion of p53
in ActD-treated cells led to the recovery of both CDC7 protein
levels and S-phase initiation, while the depletion of p53 in non-
stressed cells enhanced both the CDC7 levels and the propor-
tion of cells in S phase (Fig. 2A and B), which was consistent
across a number of independent experiments (Fig. S2C).
Interestingly, the loss of CDC7 protein in ActD-treated cells
correlated with a strong reduction in CDC7 mRNA levels
(Fig. 2C). Conversely, silencing of p53 in non-stressed cells or
prior to ActD treatment resulted in a 2.5 and 3-fold increase in
CDC7 mRNA, respectively, indicating that p53 activation leads
to downregulation of CDC7 transcript levels (Fig. 2C and
Fig. S3A).
Notably, cell treatment with ActD resulted in a 4-fold
increase of known p53 targets, miR-192/215 (Fig. S3A). The
depletion of miR-192/215 in ActD-treated cells resulted in a 4-
fold increase in CDC7 mRNA levels, conﬁrming their role in
p53-dependent down-regulation of CDC7 mRNA (Fig. S3A).
Although different control treatments (DMSO, non-targeting
siRNA) have resulted in slight rise of p53 levels, only ActD
treatment has signiﬁcantly stabilised and activated p53 as dem-
onstrated by the upregulation of p53 target p21 (Fig. S3B).
Importantly, the increase in CDC7 transcript levels after
ActD treatment of both p53- and miR-192/215 depleted cells
was reﬂected at the protein level only in p53-depleted cells
(Fig. 2D, lane 3). Only partial recovery of CDC7 protein levels
was detected in ActD-treated cells depleted of miR-192/215
(Fig. 2D, lane 5), which was negated by synthetic duplex
miRNA-192/215 mimetics (Fig. 2D, lane 6). The recovery of
CDC7 protein levels directly correlated with an increase in the
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Figure 1. DNA Damage Induces G1 Arrest via p53-dependent Down-regulation of CDC7. (A) Schematic presentation of the synchronisation protocol (see Methods).55 p53
siRNA was introduced 12h prior and irradiation (IR) 8h after the end of serum starvation. Cells were collected for analysis 4h after release from the second Aphidicolin
block. (B) Immunoblotting analysis of the nuclear extract (NE) from untreated (UT) and IR cells probed with the indicated antibodies. Orc4 was used as a loading control.
(C) Immunoblotting analysis of whole cell extracts (WCE) from synchronised IMR90 cells treated with either IR (6 Gy) or with Doxorubicin (Doxo) independently or in con-
junction with either CDC7 overexpression (CDC7WT) and/or p53 silencing (p53KD), probed with the indicated antibodies. b-actin was used as a loading control. (D) Immu-
noblotting analysis of nuclear extracts (NE) from synchronised IMR90 cells treated with either IR (6 Gy) or Doxo independently or in conjunction with either CDC7
overexpression (CDC7WT) and/or p53 silencing (p53KD), probed with the indicated antibodies. Orc4 was used as a loading control. (E) FACS analyses are shown as pie
charts to demonstrate that the G1 arrest induced by IR or Doxo can be abrogated by either p53 knockdown (p53KD) or ectopic expression of CDC7 (CDC7WT), as demon-
strated by the resumption of cell cycle progression into the S-phase.
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Figure 2. p53 Down-regulates CDC7 Transcript through miR-192/215 Pathway. (A) Immunoblotting analysis of whole cell extracts (WCE) and (B) bar diagram of cell popu-
lations with different DNA content as measured by FACS (values above the bars represent the percentage of cells with S-phase DNA content) from IMR90 cells demon-
strate an inverse correlation between p53 and CDC7 protein levels during stress induced with a low dose of actinomycin D (ActD; 1 nM) in the presence or absence of
p53 (via knockdown with siRNA). (B) Representative of 3 independent experiments. (C) qRT-PCR quantiﬁcation of relative CDC7 mRNA expression levels (-fold change) in
cells treated with either ActD or DMSO, or with p53 siRNA plus control (non-targeting) siRNANT compared with siRNANT treatment alone (CTRL). p53 silencing combined
with ActD treatment was compared to cells treated with ActD only. (C) Mean § SEM from 3 independent experiments (D) IMR90 cells were transfected with either p53
siRNA for 48h or CDC7 expressing plasmid (CDC7WT), miR-192/215 siRNA alone or miR-192/215 siRNA together with miR-192/215 synthetic mimics (miR-Mimics) for 24h
and together with a low dose of ActD (1 nM). Results were compared to either non-targeting control siRNA plus DMSO (CTRL) or ActD treated cells (ActD). Values above
the CDC7 bands indicate CDC7 mRNA levels as measured by qRT-PCR relative to the ActD treatment (lanes 1–6) and the values above the p53 bands indicate the residual
p53 mRNA after p53 silencing relative to the ActD treatment as measured by qRT-PCR (lanes 2 and 3). (E) DNA content distribution analysis of samples treated as
described in (D) is presented as a bar diagram. Values above the bars indicate the percentage of S-phase cells. Representative of 3 independent experiments.
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proportion of S-phase cells in presence of ActD and after
silencing of miR-192/215. The dose-response effects of syn-
thetic miR-192/215 mimetics were ﬁrst established in non-
stressed cells (Fig. S3F-H) and then validated in genotoxic con-
text (Fig. S3I-K). Both synthetic as well as endogenous miR-
192/215 increased after Doxo treatment targeted speciﬁcally
30UTR CDC7 reporter clone as revealed by reduction in lucifer-
ase activity (Fig S3H).
These data indicate that only a part of the p53-dependent
downregulation of CDC7 levels is achieved via miRNA-medi-
ated degradation of the CDC7 transcript.
p53 Targets CDC7 through SCF-Fbxw7 E3 Ubiquitin Ligase
We reasoned that p53 could also indirectly modulate CDC7 pro-
tein stability. This possibility was supported by experimental data
showing that the half-life of CDC7 in ActD-treated cells was
reduced~4-fold following cycloheximide treatment (Fig. 3A and SI
Data). Furthermore, the addition of the proteasome inhibitor,
MG-132, partially restored CDC7 levels, suggesting that in
stressed cells CDC7 undergoes enhanced proteolysis (Fig. 3B).
The recovered CDC7 levels after the addition of MG-132, and
separately after the inhibition of miR-192/215 (validated in
Fig. S3C-E), collectively combine to restore the CDC7 protein lev-
els observed following p53 silencing alone, suggesting that stress-
induced post-translational and post-transcriptional mechanisms
co-operate in p53-dependent CDC7 down-regulation.
The analysis of the CDC7 primary sequence has identiﬁed 5
putative degron sites, which resemble the CDC4/Fbxw7 con-
sensus phospho-degron (CPD) motif sequence, F-F-pT/PS-P-
P-X-pS/pT/E, where F corresponds to a hydrophobic residue
and X to any amino acid (Fig. 3C and D). Protein sequence
alignment analysis showed variability in CDC7 CPD conserva-
tion (Fig. S4A), with CPD3 being completely conserved in the
compared species and CPDs 4 and 5 most closely resembling
the consensus CDC4/Fbxw7 recognition motif that appears to
prefer the Thr-Pro residue pair at its start.30 Structural informa-
tion is currently available only for CPD3 motif, with other 4
CPDs located in regions missing in the available crystal struc-
ture for CDC7.31 Using structure modeling we predicted the
positions of the remaining CPDs on the CDC7 structure
(Fig. 3E and Fig. S4B).
The conserved threonine residues in the 3 CPD motifs were
mutated to alanine (CPDs 3–5: Thr376Ala, Thr472Ala and
Thr503Ala) to test whether the resulting CDC7CPD mutant pro-
tein can resist degradation via the p53-dependent pathway in
cells treated with ActD. Ectopic expression of either CDC7WT
or CDC7CPD proteins enhanced the S phase population of
IMR90 cells by 25% and 23%, respectively. Furthermore, the
CDC7CPD protein was resistant to treatment, remained at high
levels, and cells harbouring CDC7CPD had unrestrained S-phase
entry, despite the presence of stress. Furthermore, ectopic
expression of either CDC7WT or CDC7CPD proteins enhanced S
phase population of non-stressed IMR90 cells by 15% and 13%
respectively (Fig. 3F and G). Likewise, expression of CDC7WT
or CDC7CPD in ActD-treated IMR90 cells enhanced S phase
population by 27% and 21%, respectively (Fig. 3F and G). The
CDC7CPD protein was more efﬁcient in rescuing CDC7 levels
during ActD treatment compared to CDC7WT ectopic expres-
sion (Fig. 3F and Fig. S5A). Notably, levels of CDC7 in ActD-
treated cells remained reduced (~0.4-fold) compared to the non-
treated control, while ActD-treated cells transfected with
CDC7CPD showed~8-fold increase of CDC7 levels, compared to
~5.4-fold increase measured in ActD-treated cells transfected
with CDC7WT (SI Data and Fig. 3F). These data indicate that
the CPD motifs are required for proteolytic degradation of
CDC7 in stressed cells via the p53-dependent pathway.
Interestingly, overexpression of either CDC7WT or
CDC7CPD in this experiment signiﬁcantly reduced p53 levels in
both non-stressed and ActD-treated cells (Fig. 3F), suggesting
the existence of a negative feedback pathway by which CDC7
can inﬂuence p53 levels. We compared the p53 levels in both
non-stressed and ActD-treated cells after exposure to CDC7WT
or CDC7CPD for 24h and 48h (Fig. S5B). The p53 levels were
unaffected after CDC7 overexpression for 24h, but signiﬁcantly
dropped after 48h, which was also reﬂected by the change in
the levels of the p53 targets Mdm2 and p21, indicating that
CDC7-dependent negative feedback onto p53 appears to be
time-dependent and requires sustained overexpression of
CDC7. Comparative transfections of cells with CDC7WT or
CDC7CPD, CDC7T/A (Thr376 substituted with Ala) and
CDC7T/E (Thr376 substituted to Glu) yielded similar results
after 24h, such that the p53 levels were unaffected (Fig. S6).
In order to understand how CDC7 might inﬂuence the sta-
bility of p53 we expressed CDC7WT, CDC7CPD and CDC7KAD
(the catalytically-inactive mutant of CDC7) for 24h and 48h in
context of ActD-incurred stress and compared their effect on
p53 levels. The mutants CDC7WT and CDC7CPD, but not
CDC7KAD, reduced the levels of p53, indicating that CDC7
kinase activity is important for the negative feedback onto p53
(Fig. S6B). Efﬁcient depletion of Mdm2 by siRNA (Fig. S6B
and C) restored the p53 levels, indicating that CDC7 suppres-
sion of p53 levels might directly or indirectly involve Mdm2.
Given that Fbxw7b is a bona ﬁde p53 transcriptional target32
and an E3 ubiquitin ligase, which speciﬁcally interacts with CPD
motifs, we next tested whether this protein was up-regulated by
p53 in ActD-treated cells. The results show that Fbxw7b protein
levels were increased, whereas neither APC speciﬁc-Cdh1 and
CDC20, nor b-TrCP and Skp2, demonstrated p53-dependent up-
regulation (Fig. 4A). Notably, the anti-Fbxw7 antibody was speciﬁc
for the Fbxw7b isoform present in the cytoplasm, as demonstrated
by the subcellular fractionations (Fig. S7A and B), and this cyto-
plasmic Fbxw7b was upregulated upon ActD treatment (Fig. S7B).
Furthermore, the depletion of Fbxw7b by siRNA led to the accu-
mulation of CDC7 in non-stressed cells and the recovery of CDC7
protein levels in ActD-treated cells, allowing ActD-treated cells to
enter into S-phase (Fig. 4B and C).Moreover, CDC7was efﬁciently
co-immunoprecipitated with an anti-ubiquitin antibody (and vice-
versa) from IMR90 and HCT116 cell extracts but not from
HCT116 Fbxw7(CDC4)¡/¡ cells (Fig. 4D and E). Unlike IMR90
cells where ubiquitin-modiﬁed CDC7 was detected in presence or
absence of stress (ActD), ubiquitination of CDC7 in non-stressed
HCT116 cells was below detectable levels (compare Fig. 4D lanes-
12 and 13 with Fig. 4e lanes-11 and 12) after inhibition of protea-
some byMG-132, indicating that CDC7 levels are stabilised in can-
cer cells at the steady-state. The p53-dependent CDC7 regulation
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Figure 3. Stress-induced Proteolysis of CDC7 is Dependent on CDC4-type Phospho-degrons (CPDs). (A) IMR90 cells were treated with cycloheximide (CHX, 10 mg/ml) in
the presence of either DMSO (CTRL) or Actinomycin D (ActD; 1nM). Cells were harvested at the indicated time points and whole cell extracts (WCE) were analyzed by
immunoblotting with an antibody against CDC7. (B) Immunoblotting analysis of WCE prepared from IMR90 cells that were ﬁrst treated with either p53 siRNAs (48h) or
miR-192/215 siRNA (24h) and then treated with ActD in the presence or absence of MG-132 (10 mM). (C) The putative Fbxw7 recognition motifs (CPDs) in the CDC7 pro-
tein sequence. The CDC4-phospho degron (CPD) consensus sequence is xT/SPxxT/S/x, where x is any amino acid residue. (D) Alignment of the phosphodegron motifs
(CPDs) present in known Fbxw7 substrates with 5 CPDs in the CDC7 primary protein sequence. Positions of the key amino acid residues are highlighted in blue. (E) CDC7
structure (PDB 4f9a) shown as a ribbon with indicated positions of CPDs. Positions of CPDs 1, 2, 4 and 5 were predicted by modeling using iTasser and Phyre2 (see Meth-
ods and Fig. S4); Thr 376 in CPD3 is shown in red, ATP is shown in magenta and the Mg atom is shown as a yellow sphere. (F) CDC7 mutated on CPDs (CPDs 3, 4 and 5,
CDC7CPD) and ectopically-expressed for 48h in IMR90 cells demonstrated more pronounced resistance to degradation compared to CDC7WT in the absence or presence of
ActD (1 nM). CTRL represents empty vector and DMSO treatment; b-actin was used as a loading control. (G) DNA content distribution analysis of samples analyzed in (F)
shown as a bar diagram. Values above the bars indicate the percentage of cells with S-phase DNA content. (G) Representative of 3 independent experiments.
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in HCT116 cells was conﬁrmed using isogenic p53C/C and p53¡/¡
lines, which showed that in the absence of p53, CDC7 levels remain
stable after ActD treatment (Fig. S7C).
Finally, we tested whether Fbxw7b-dependent degradation of
CDC7 may require phosphorylation of CDC7 CPDs by GSK3b
kinase, which is also a p53 activation target.30,33 Cross-immunopre-
cipitations indicated the formation of complexes between CDC7
and Fbxw7b, as well as GSK3b kinase (Fig. S7D). Moreover,
GSK3b phosphorylated CDC7 threonine residues in vitro (Fig. 4F),
without affecting the CDC7 Thr376, the CDK2-speciﬁc phosphor-
ylation site,18 suggesting that GSK3b phosphorylates CDC7 on
threonine sites other than Thr376.
miR-192/215- and Fbxw7b dependent pathways cooperate
in stress-induced p53-dependent downregulation of CDC7
We next used silencing of p53, miR-192/215, Fbxw7b and
GSK3b to determine whether these novel post-transcriptional
(via miR-192/215) and post-translational (via GSK3b/Fbxw7b)
p53-dependent pathways act individually or cooperate in
CDC7 down-regulation in IMR90 and HCT116 colorectal
cancer cells (Fig. 5). First we tested the impact of down-regulat-
ing p53, miR-192/215, Fbxw7b and GSK3b in non-stressed
cells and compared their impact to the ectopic expression of
CDC7 alone (Fig. 5A-C). Single and combined depletions of
p53, miR-192/215, Fbxw7b and GSK3b, unlike Cdh1 depletion,
stabilised CDC7, indicating that the p53-dependent pathways
are involved in the basal regulation of CDC7 levels. The deple-
tions also led to a marked stimulation of cyclin A levels and
DNA synthesis (Fig. 5A and B).
Next, we compared the impact of p53-dependent CDC7 reg-
ulators in stressed IMR90 (non-transformed) and HCT116
(cancer) cell lines (Fig. 5D-G). In IMR90 cells, Doxo treatment
induced p53 upregulation, accompanied by complete downre-
gulation of CDC7, which was partially reversed by silencing of
either miR-192/215 or GSK3b/Fbxw7b (Fig. 5D and E). Com-
bined depletion of miR-192/215 and Fbxw7b in IMR90 cells
resulted in CDC7 protein recovery, reﬂecting the effect
obtained by silencing p53 (Fig. 5D, lane 6 and lane 3). Similar
effects were observed in IMR90 cells depleted of p53, miR-192/
215, Fbxw7b and GSK3b in the presence or absence of ActD-
induced stress (Fig. S8A and B).
Figure 4. Stress-induced CDC7 Proteolysis is Mediated by Fbxw7b and GSK3b kinase. (A) Immunoblotting analysis of whole cell extracts (WCE) from IMR90 cells after
treatment with Actinomycin D (ActD; 1 nM, 24h) in the presence or absence of p53 siRNA. Samples probed with anti-Fbxw7b antibody (Fbxw7b) were prepared from
cytoplasmic fractions. (B) Immunoblotting analysis of WCE with the indicated antibodies demonstrates CDC7 stabilization after Fbxw7b silencing (Fbxw7bKD) for 48h in
control (CTRL) IMR90 cells or IMR90 cells treated with ActD for 24h. CTRL represents non-targeting siRNA and DMSO treatment. (C) DNA content distribution proﬁles for
the indicated treatments as described in (B) presented as a bar diagram. Values above the bars indicate the percentage of cells with S-phase DNA content. (C) Representa-
tive of 3 independent experiments. (D and E) Immunoblotting analysis of WCE after CDC7 or ubiquitin pull-down in (d) IMR90 or (e) HCT116 Fbxw7C/C and Fbxw7¡/¡ cells
in the presence or absence of ActD (1nM, 24h with DMSO as a negative control) and the proteasome inhibitor MG-132 (10 and 20 mM for IMR90 and HCT116, respectively)
where indicated. Ubiquitinated CDC7 is revealed in presence or absence of stress (ActD) only after inhibition of the proteasome MG-132. The intense cut band on the bot-
tom are immunoblobulins (Ig) (F) Immunoblotting analysis of the in vitro kinase assay reactions performed using the recombinant active CDC7/ASK kinase complex in the
presence or absence of recombinant active GSK3b and the presence or absence of ATP. The reaction samples were analyzed with 2 different anti-phospho-threonine anti-
bodies (pThr Ab1 and pThr Ab2), anti-pThr376 (CDC7 pT376) and an antibody recognizing all phosphorylated serines (pSer). Recombinant protein loading was controlled
with anti-CDC7 and anti-GSK3 antibodies and antibodies speciﬁcally detecting the GST and His tags.
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Figure 5. Post-transcriptional and Post-translational p53-dependend Pathways Cooperate to Down-regulate CDC7 in Cells Undergoing DNA Damage. (A) Immunoblotting
analysis of whole cell extracts (WCE) from IMR90 cells treated with either p53 siRNA, miR-192/215 siRNA, Fbxw7b shRNA, a combination of miR-192/215 siRNA and
Fbxw7b shRNA, GSK3b siRNA or Cdh1 siRNA. b-actin was used as a loading control. (B) DNA content distribution analysis of indicated samples as described in (A) is
presented as a bar diagram. Values above the bars represent the percentage of cells with S-phase DNA content. (B) Representative of 3 independent experiments. (C)
Residual p53-, Fbxw7b-, miR-192/215- and GSK3b mRNA as measured by qRT-PCR in percentages (%) relative to the respective control (CTRL). (C) Mean § SEM from 3
independent experiments (D) 2 mM Doxorubicin (Doxo) was added to IMR90 cells for 48h, after 24h pre-treatment with either p53 siRNA, miR-192/215 siRNA, Fbxw7b
shRNA, a combination of miR-192/215 siRNA and Fbxw7b shRNA or GSK3b siRNA. CTRL represents the combination of non-targeting control siRNA and DMSO treatment.
(E) DNA content distribution analysis of indicated samples as described in (D) is presented as a bar diagram. Values above the bars represent the percentage of cells with
S-phase DNA content. (E) Representative of 3 independent experiments. (F) 1 nM Actinomycin D (ActD) was added to HCT116 cells for 24h, after 24h pre-treatment with
following siRNAs: either p53 siRNA, miR-192/215 siRNA, Fbxw7b shRNA, a combination of miR-192/215 siRNA and Fbxw7b shRNA or GSK3b siRNA. CTRL represents the
combination of non-targeting control siRNA and DMSO treatment. (G) DNA content distribution analysis of indicated samples as described in (F) is presented as a bar
diagram. Values above the bars represent the percentage of cells with S-phase DNA content. (G) Representative of 3 independent experiments.
CELL CYCLE 2965
Interestingly, there were differences in the recovery of CDC7
levels in normal and cancer cells when CDC7-down-regulating
pathways were blocked separately or together. In IMR90 cells,
the blocking of either pathway contributed to a better recovery
of CDC7 levels by Fbxw7b silencing, and when both pathways
were blocked the recovery of CDC7 levels was almost complete
(Fig. 5D, lanes 4, 5 and 6 respectively and Fig. S8A and B). In
HCT116 cells, however, blocking the Fbxw7b pathway led to a
higher degree of CDC7 levels recovery than blocking the miR-
192/215 pathway or combined depletion of miR-192/215 and
Fbxw7b (Fig. 5F, lane 5 versus lane 4 and lane 5 vs. lane 6,
respectively). In keeping with this, the S-phase population of
Doxo-treated IMR90 cells was highest after combined pathway
silencing (18%) and almost recovered to the level of the control
cells (20%), whereas individual pathway blocking led to 14%
and 16% recoveries for miR-192/215 and Fbxw7b depletion,
respectively (Fig. 5E). ActD-treated HCT116 cells, however,
recovered their S-phase population after both individual and
combined silencing of miR-192/215 and Fbxw7b (18%, 20%
and 19%, respectively, compared with 22% for the S-phase pop-
ulation in untreated cells) (Fig. 5G). These results showed that
both p53-dependent pathways (via miR-192/215 and GSK3b/
Fbxw7b) contribute to CDC7 down-regulation and act syner-
gistically to achieve complete removal of CDC7 upon stress.
p21 complements the CDC7 downregulation under stress
We next tested whether there is any crosstalk between known
p53-p21-CDK2 and novel p53-CDC7 pathways. To that end,
we silenced p21 in Doxo-treated IMR90 cells and cells treated
with both Doxo and miR-192/215 inhibitors (Fig. 6A and B).
Silencing of p21 during Doxo-induced stress led to the recovery
of CDK2 activity, which was reﬂected in CDC7 phosphoryla-
tion at Thr376 (CDC7 pT376) (Fig. 6A, lanes 5 and 6). CDC7
pT376 is normally present in cycling cells18 and was lost when
cells were treated with Doxo and only recovered when either
p53, or p21 was depleted in presence or absence of miR-192/
215 (Fig. 6A lanes 3, 5 and 6). The fraction of S-phase (15%) in
p21-silenced cells was similar to the S-phase population of
Doxo-treated cells after miR-192/215 inhibition (16%), whereas
the S-phase population following combined inhibition of miR-
192/215 and p21 silencing was more pronounced (21%) and
Figure 6. p21 complements the CDC7 downregulation under stress. (A) Levels of CDC7 and its downstream target MCM2 (phospho-Ser) pS10856 protein according to
immunoblotting analysis of WCE after silencing p53 (p53KD) for 48h compared to the combination of miR-192/215 silencing and/or p21 silencing in Doxorubicin (Doxo)
treated IMR90 cells. (B) Efﬁciency of p21 silencing (%) in cells treated with Doxo or Doxo and miR-192/215 siRNA as measured by qRT-PCR. (C) Mean § SEM from 3
independent experiments (C) DNA content distribution proﬁles of indicated treatments in (A) presented as a bar diagram. Values above the bars represent the percentage
of cells with S-phase DNA content. (C) Representative of 3 independent experiments. (D) Immunoblotting analysis of the WCE from HCT116 p21¡/¡ and p21C/C cells in
the presence or absence of Actinomycin D (ActD; 1 nM, 24h, DMSO as a negative control) and CDK2 silencing (CDK2KD) shows a reduction of CDC7 levels in p21¡/¡ cells
after CDK2- and CDC7 phospho-Thr376 (CDC7 pT376) inhibition. (E) DNA content distribution proﬁles of samples described in (D) presented as a bar diagram. Values
above the bars represent the percentage of cells with S-phase DNA content. (E) Representative of 3 independent experiments. (F) Effect of CDK2 inhibition by Roscovitine
(Rosco, 40mM) on CDC7 recovery after p21 silencing in ActD-treated IMR90 cells as detected by immunoblotting. Phospho-Thr376 (pT376) CDC7 antibody was used to
assess CDK2 inhibition by Rosco. (G) Immunoﬂuorescence analysis of CDC7 levels in HCT116 p21¡/¡ cells treated with either DMSO control, ActD (1 nM) or ActD (1 nM)
and p21 siRNA in the presence or absence of Rosco (40 mM). Actin immunostaining (FITC) was used to visualize the cytoplasm.
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comparable with the S-phase population of Doxo-treated cells
with depleted p53 (19%) (Fig. 6C).
In order to uncover the role of p21 in CDC7 stability, we
next treated isogenic HCT116 p21C/C and p21¡/¡ cell lines with
ActD. After 24h treatment CDC7 levels were reduced in p21C/C
cells but remained stable in p21¡/¡ cells and were only reduced
when CDK2 was silenced, which led to decreased phosphoryla-
tion of CDC7 on Thr376 (Fig. 6D). The efﬁciency of CDK2
silencing was conﬁrmed by qRT-PCR (Fig. S9A). In p21¡/¡
cells, the reduction of CDC7 levels was reﬂected by a drop in
the proportion of S phase cells from 33% (ActD treatment only)
to 12% when ActD treatment was combined with CDK2 silenc-
ing (Fig. 6E). CDK2 knockdown in IMR90 cells resulted in a
reduction of CDC7 Thr376 phosphorylation similar to ActD
treatment alone (Fig. S9B). These results demonstrated that
CDC7 Thr376 is a CDK2 phosphorylation site and that CDK2
depletion in p21¡/¡ cells leads to degradation of CDC7.
We next used isogenic HCT116 cancer cell lines with a
genetic knockout of p53, Fbxw7 (CDC4) or p21 and treated
these cells with ActD for 24h (Fig. S10A and B). In keeping
with the previous observations,34 the p53 levels were up-regu-
lated in control non-stressed p21¡/¡ cells compared to p21C/C
cells. However, the levels of CDC7 were similar in p21¡/¡ and
p21C/C cells and lower when compared with p53 and Fbxw7
isogenic cell lines. This low level of CDC7 was not affected by
ActD treatment of p21¡/¡ cells compared with p21C/C cells
(Fig. S10A). Consistent with our previous data, the levels of
CDC7 did not decrease in cells lacking p53 and partially
decreased in Fbxw7¡/¡ cells (Fig. S10A). Unlike in HCT116
p53C/C, p21C/C and Fbxw7C/C cells, ActD treatment did not
inﬂict reductions to the S-phase population in p53¡/¡,
Fbxw7¡/¡ and p21¡/¡ cells (Fig. S10B).
Moreover, similar to the CDK2 knockdown, treatment with
increased concentrations of the CDK2 inhibitor Roscovitine
(Rosco), which mimics the presence of p21, led to a dose-
dependent reduction of CDC7 levels in ActD-treated p21¡/¡
cells, which was reﬂected in a reduction of CDC7 pT376 levels
(Fig. S10C), conﬁrming that CDK2 inhibition is relevant for
CDC7 degradation. The combination of Rosco and ActD treat-
ments reduced the number of cells in the S-phase (Fig. S10D)
while inducing G2/M cell enrichment as previously reported.35
As expected, treatment with Rosco blocked the recovery of
CDC7 levels in IMR90 cells treated with ActD and p21 siRNA
(Fig. 6F, lane 5 versus lane 4 and Fig. 6G). These data indicate
that p21 facilitates the p53-dependent degradation of CDC7
upon stress by inhibiting CDK2 and by negating the phosphor-
ylation of CDC7 at Thr376 (CPD3).
CDC7 exerts negative feedback to p53 which leads to
DNA damage
Prompted by the results showing CDC7-dependent negative
feedback onto p53, we tested the effects of the sustained expres-
sion of CDC7WT and CDC7KAD proteins in non-transformed
IMR90 cells. To achieve this, we transfected CDC7WT and
CDC7KAD constructs in IMR90 cells every 48h for a total of
20 days. We observed efﬁcient expression of both CDC7WT and
CDC7KAD proteins (Fig. 7A and B). Importantly, when
CDC7WT was expressed the p53 levels were depleted when
compared to control expression; however, when CDC7KAD was
expressed the p53 levels remained stable (Fig. 7A and B).
Moreover, cells transfected with CDC7WT showed accumu-
lation of DNA damage with the presence of gH2A.X.36 In con-
trast, control- or CDC7KAD-expressing cells did not accumulate
DNA damage (Fig. 7A and B). In spite of the DNA damage,
CDC7WT expressing cells showed a gradual rise in the S phase
proportion (Fig. 7C). Thus, the sustained expression of active
CDC7 kinase leads to suppression of p53, accumulation of
DNA damage, and unrestrained S-phase entry despite the
DNA damage.
Discussion
To maintain genomic stability, cells have to synchronise DNA
damage repair and replication with the cell cycle, and the p53
tumor suppressor is central to this process. Here we have dem-
onstrated that the p53-dependent G1 arrest following DNA
damage is mediated via 2 separate signaling axes (Fig. 7D). We
have shown for the ﬁrst time that in addition to the p53-depen-
dent inhibition of CDK2, blocking of the G1/S transition also
requires the p53-dependent targeting of CDC7, a second key
kinase involved in DNA origin ﬁring. This pathway consists of
CDC7 transcript down-regulation via miRNAs 192/215 and
CDC7 protein degradation via Fbxw7b E3 ubiquitin ligase. The
two arms of the novel pathway combine to reduce levels of
CDC7 kinase efﬁciently in cells that are subject to genotoxic
stress, thereby halting both cell cycle progression and origin ﬁr-
ing. Using two separate molecular mechanisms may allow p53
to establish a temporal element of control over CDC7 levels,
with Fbxw7b- providing a rapid way to eliminate large amounts
of CDC7 protein, while the miR-192/215 down-regulating
CDC7 transcript.
Importantly, our data shows that the 2 p53-dependent signal-
ing pathways regulating CDK2 and CDC7 are interlinked
(Fig. 7D). Here we discovered that CDK2 inhibition by p21 abro-
gates Thr376 phosphorylation of CDC7, which facilitates
Fbxw7b-mediated CDC7 degradation, in a similar fashion to
Ser54 in CDC6 which then leads to Cdc6 degradation and block-
ing of MCM recruitment to the origins.16 Through these inter-
linked pathways p53 is therefore able to mediate a powerful G1/S
phase arrest in response to genotoxic insult via inhibition of pre-
RC assembly and suppression of DNA origin ﬁring. Interestingly,
our data suggests the existence of further cross talk between the
p53-p21-CDK2 and the p53-[miR-192/215 Fbxw7b]-CDC7 sig-
naling axes. Thus, we observed that abrogation of G1/S arrest by
CDC7 overexpression is linked to a recovery of CDK2 activity
and a reduction in p21 levels. In contrast, reducing CDC7 levels
in response to stress provides an important trigger of G1/S arrest
by the p53-dependent DNA origin activation checkpoint
(OAC)37-39 (Fig. 7E). The role of p53 in reducing CDC7 levels,
and the fact that CDC7 is an integral component of the OAC,
might incur a potential positive feedback loop on the G1/S arrest,
thereby assuring continuous protection of the genome until DNA
repair is completed. Thus, loss of p53 will not only abrogate the
OAC but also will increase the levels of the CDC7.
In this context, loss of p53 will affect the basal proliferation
since perturbing one of p53-dependent pathways (miR-192/
215 or Fbxw7b) resulted in enhanced proportion of cells in the
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S phase due to stabilised CDC7. These results indicate that p53-
CDC7 regulatory pathway could at least in a part determine the
cellular turnover, worth addressing in the future.
The importance of CDC7 downregulation is further re-iter-
ated in the fact that over-expression of CDC7 in cells undergo-
ing DNA damage was sufﬁcient to override p53-induced G1/S
arrest, permitting cells to enter S-phase despite their genomes
being severely damaged, in keeping with the oncogenic poten-
tial of CDC7 and CDC7-dependent malignancies.20,22
The oncogenic potential of sustained CDC7 overexpression
was supported by our data revealing a novel negative feedback
loop from CDC7 to p53. Notably, this feedback requires CDC7
kinase activity and might involve Mdm2 (Fig. S6B and C). The
exact mechanism of Cdc7 negative feedback on p53 warrants
further detailed investigation.
In the context of abrogation of cell cycle control, it appears
that CDC7 overexpression has different effects on G1/S, S and
G2/M transitions. Thus, in G1, high levels of CDC7 suppress
the p53 pathway via negative feedback loop to override the
p53-CDC7 G1/S checkpoint leading to an unrestrained entry
into S-phase. In contrast, during S phase compromised DNA
replication is dealt with by the ATR/Chk1 checkpoint leading
to CDC7 stabilization which prevents replication fork collapse
(Fig. 7E).40,41 Similar to oncogenic CDC642 and given the role
of CDC7 in the ATR/Chk1 checkpoint,43,44 it is possible that
oncogenic levels of CDC7 can inﬂuence the G2/M arresting
pathway.
Interestingly recent work by Galanos et al.45 indicated that
prolonged expression of p21 in p53-deﬁcient cells can deregu-
late DNA replication leading to genomic instability further
consolidating CDC7 as a potent anti-cancer target in p53
mutant tumors.37,46-48
In summary, this study shows that the p53-induced G1 growth
arrest following genotoxic stress is critically dependent on the p53-
[miR-192/215; Fbxw7b]-CDC7 signaling pathway, in addition to
the classical p53-p21-CDK2 pathway. The parallel and synergistic
action of these pathways therefore represents a novel and funda-
mental cell cycle mechanism, a p53-linked regulatory network that
Figure 7. Sustained overexpression of active CDC7 down-regulates p53, abrogates S-phase entry control and leads to DNA damage - biological implications of the p53-
CDC7-regulatory pathway. Whole cell extracts (WCE) from IMR90 cells transfected every 48h with either wild type- (CDC7WT) in (A) or the kinase-inactive CDC7 (CDC7KAD)
mutant in (B) over a 20 day time course and immunoblotting analysis for CDC7, p53 and gH2A.X levels (DNA damage marker). Cells transfected with an empty vector con-
trol (CTRL) acted as a negative control in both (A) and (B). b-actin was used as a loading control throughout. (C) DNA content distribution proﬁles of indicated treatments
in (A) presented as a bar diagram. Values above the bars represent the percentage of cells with S-phase DNA content. (C) Representative of 3 independent experiments.
(D) Schematic representation of the p53-dependent pathways responsible for controlling G1/S transition. The novel pathway is shown in blue. Genotoxic stress (irradia-
tion, DNA damage and cytotoxic drugs) stabilises and activates the p53 tumor suppressor. p53 then transcriptionally up-regulates p21, which inhibits CDK2 activity and
consequently prevents the CDK2-dependent phosphorylation of CDC7 at Thr376 located in CDC4-phosphodegron 3 (CPD3). Likewise, phosphorylation of Ser54, a CDK2
target in CDC6, is prevented, marking it for degradation by the APC/Cdh1 complex. Lack of CDC7 Thr376 phosphorylation facilitates CDC7 phosphorylation by stress-
induced GSK3b on the other CPDs, and leads to the subsequent interaction with Fbxw7b E3 ubiquitin ligase and degradation. p53 induces both miR-192/215 which
provides CDC7 transcript down-regulation, and Fbxw7b which targets CDC7 protein for degradation in response to genotoxic stress. CDC7 exerts negative feedback onto
p53 through its kinase activity. The feedback loop allows CDC7 to retain its high levels and ensures cell entry into S-phase. (E) Stress-related CDC7-dependent cell cycle
checkpoints. Genotoxic stress triggers (1) p53-dependent downregulation of CDC7 and (2) activation of a p53-dependent DNA origin activation checkpoint (OAC) inducing
a robust G1/S cell cycle arrest.37-39 Increased CDC7 activity can down-regulate p53 levels via a negative feedback loop (3) and override the G1/S checkpoint. During S
phase (4) in response to replication stress, activation of the ATR/Chk1 checkpoint results in stabilization of CDC7 that prevents replication fork collapse (40, 41). DNA-RI -
DNA replication initiation.
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plays an important role in mediating G1 growth arrest in response
to genotoxic insult.
Methods
Cell culture and cell synchronisation
Wild type and HCT116 p53¡/¡, HCT116 p21¡/¡ and HCT116
Fbxw7 (Cdc4)¡/¡ cell lines were a kind gift from Dr Bert Vogel-
stein. IMR90 (ATCC# CCL-186), a diploid human ﬁbroblast
cell line, was obtained from LGC Standards (Middlesex, UK) at
population doubling (PD) 10. IMR90 cells were cultured at
37C and 5% CO2 in DMEM (Invitrogen, Paisley, UK), supple-
mented with 10% FCS (Invitrogen), 100 U/ml penicillin and
100 mg/ml streptomycin. For the preparation of synchronous
cell populations, IMR90 cells were treated with 2 consecutive
blockades, for G0/G1 enrichment, by starvation with 0.1% FCS
for 72 h and for G1/S enrichment, by the addition of Aphidico-
lin (5 mg/ml) (Sigma) for 12 h, separated by an interval of 12h
in FCS-complemented medium. Cells were harvested for analy-
sis 4 h after release from the second block.
Actinomycin D, Doxorubicin, Cycloheximide, Roscovitine
and MG-132 were purchased from Sigma. GSK3b inhibitor
VIII49 was purchased from Calbiochem.
Doxorubicin was used at 2 mM ﬁnal concentration. Ionising
irradiation of 6 Gy/min was performed using an AGO HS X-
Ray System Model CP320 with a Varian NDI-321 X-ray tube
of 320kV and an oil cooled stationary anode metal ceramic
X-ray source.
Cell cycle analysis
Flow cytometric cell cycle analyses were performed using
Beckman Coulter CyAN ADP as described elsewhere. Gating
and analysis of FACS histograms were performed using FlowJo
software (Tree Star, Inc. USA).
Cell fractionation and immunoprecipitation
For immunoblotting analysis, cells were harvested and whole
cell extracts (WCE) and subcellular fractions were prepared in
modiﬁed RIPA buffer.37 Chromatin-bound fraction (CBF) was
isolated as described previously.37 Subcellular fractionation and
in vitro kinase assays were performed as described previously.37
Phosphorylation of truncated Rb (CDK2 substrate; QED Bio-
science, San Diego, CA) was detected with anti-Rb phospho Ser
612 antibody (Invitrogen).
The recovery of CDK2 activity after ectopic expression of
CDC7 in stressed cells was assessed by in vitro kinase assay.37
Luciferase assay was obtained from Promega and performed
according to manufacturer’s instructions in lysates from
HCT116 cells co-transfected with 30UTR luciferase reporter
clone of CDC7 (OriGene) and miR-192/215 synthetic mimetics
(Qiagen, Ltd.).
Immunoblotting
Protein concentration was determined using the DC Bio-Rad
protein assay kit (Bio-Rad Hemel Hempstead, UK). 15–60 mg
of total protein was loaded in each lane and separated by 4% to
20% SDS-PAGE. Protein was transferred from polyacrylamide
gels onto PVDF membranes (Bio-Rad) by semi-dry electroblot-
ting. Blocking, antibody incubations and washing steps were
performed as described.22 The antibodies used for immuno-
blotting (see below) included: Rb, CDK2, GSK3, Fbxw7, c-
MYC (N-262), Skp2, Cdc-20 and Rad51 from Santa Cruz
(Santa Cruz, CA); Orc4, MCM2 (BM28), p21 and b-TrCP
from BD Biosciences (Oxford, UK); ubiquitin from Abcam
(Cambridge, UK), p53 (Ab-6); Cdh1 from Merck (Beeston,
UK); CDC7 and CDC7 phospho-Thr376 from MBL Interna-
tional (Woburn, MA); b-actin from Sigma (Gillingham, UK);
p53 phospho-Ser-15 and phospho-histone gH2A.X (Ser-139)
from New England Biolabs (Hitchin, UK); and Rb phospho-Ser
612 from Invitrogen. Afﬁnity-puriﬁed rabbit polyclonal anti-
geminin antibody G95 was generated as described.50 The
immunoblot images were scanned, and densitometric analysis
of the immunodetected protein bands was performed using
ImageJ software (SI Data).
RNA interference
CDC7 and p53 mRNA depletion was performed with double-
stranded RNA custom oligos as previously described,37 while
miR-192/215 levels were silenced by custom inhibitors with tar-
geting sequence AAUUGACAGCCAGUGCUCUCGUU for
miR-192 and AAUGACCUAUGAAUUGACAGAUU for miR-
215 purchased from Thermo Scientiﬁc Dharmacon. p21,
GSK3b and ASK (Dbf4) SMART pool siRNAs were purchased
from Thermo Scientiﬁc Dharmacon. shFbxw7b was obtained
under the cloning code HNRCLO-136632 from NKI Cancer
Speciﬁc pRetroSuperCam shRNA library of the Scientiﬁc Serv-
ices at the Wolfson Institute for Biomedical Research (UCL,
London, UK). Non-targeting siRNA (Invitrogen) was used as a
negative control. Lipofectamine RNAiMAX (Invitrogen) was
used in all transfections according to the manufacturer’s rec-
ommendations. The transient transfections were performed
(see Ref 37) using 10 nM of either CDC7, p53, GSK3 and p21
duplex, or a mixture of 10 nM miR-192 and 10 nM miR-215
(referred to as miR-192/215). siRNAs and inhibitors were used
according to the manufacturer’s instructions (Invitrogen).
For p53 knockdown, cells were incubated for 24 to 72h
depending on the experimental setup, for miR-192/215 deple-
tion for 48h, and for Fbxw7 knockdown for 24h. All experi-
ments were performed at least 3 times. QRT-PCR and
immunoblotting were used to conﬁrm selective silencing of the
corresponding proteins.
Cell transfections
For rescue experiments, the full 1725 bp CDC7 cDNA sequence
inserted into pCMV6-AC expression vector (OriGene) was
used, as described in.37 The speciﬁcity of miR-192/215 inhibi-
tion was tested with a rescue experiment using a cocktail of
synthetic miR192/215 mimics (Qiagen Ltd.). pCMV6-AC
CDC7CPD (CDC7 Thr376A/Thr472A/Thr503A), pCMV6-AC
CDC7T/A (CDC7 Thr376A), pCMV6-AC CDC7T/E (CDC7
Thr376E) and pCMV6-AC CDC7KAD (CDC7 catalytically inac-
tive - K90A; D196A) were generated synthetically (Geneart;
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Life Technologies). 30 UTR luciferase reporter clone of CDC7
for miRNA validation was obtained from OriGene. All plasmid
DNAs used for transfection were prepared with a Plasmid
Maxi Prep Kit (Qiagen) following the manufacturer’s protocol,
and their quality and integrity was assessed by DNA sequenc-
ing. Transfection of the plasmids was performed using Lipo-
fectamine LTX according to the manufacturer’s instructions.
RNA extraction and qRT-PCR
To evaluate the efﬁciency of transfection with CDC7, p53, p21,
CDK2, Mdm2, GSK3b, Fbxw7b and miR-192/215 mimics,
mRNA transcription levels were assessed by qRT-PCR. Total
RNA was isolated using a PureLink Micro-to-Midi kit (Invitro-
gen) according to the manufacturer’s instructions. Reverse
transcription reactions using 40 ng of total RNA were per-
formed in a one step process using a SuperScript III Platinum
SYBR Green One Step qRT-PCR Kit (Invitrogen). Melting tem-
peratures (Tm) used for the annealing step were 47C for
CDC7, 50C for p53 and 54C for miR-192/215. Relative quan-
tiﬁcations were obtained using the comparative Ct method with
Realplex software according to the manufacturer’s protocol
(Eppendorf, Heidelberg, Germany). Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used to normalize each of
the extracts for ampliﬁable human DNA. Primers were pro-
vided by Euroﬁns MWG Operon (Ebersberg, Germany). Cycle
conditions and primers are available upon request. For miR-
192/215 relative quantiﬁcation, ﬁrst speciﬁc cDNA was synthe-
sized using LNA-modiﬁed primers for miR-192 and miR-215
and miRCURY LNA Universal RT microRNA cDNA Synthesis
Kit from Exiqon (Vedbaek, Denmark), followed by qRT-PCR
using a QuantiFAST SYBR Green Kit from Qiagen. MiR-16
purchased from Exiqon (Vedbaek, Denmark) was used as the
normalizing control. The PCR conditions for miR-192/215
were as follows: initial activation at 95C for 5 min then 40
cycles of 95C for 10s and 60C for 30s with a ramp rate of
1.6C/s.
CDC7 protein sequence and structure analysis
CDC7 primary sequence was analyzed using ExPASy Bioinfor-
matics Resource portal tools
http://www.expasy.org/proteomics and ELM51 (http://elm.
eu.org/). Multiple protein sequence alignment was prepared by
using CLUSTALW.52
CDC7 structural modeling has been performed by using
Phyre253 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?
id=index) and i-TASSER54 (http://zhanglab.ccmb.med.umich.
edu/I-TASSER/). Illustrations were generated using PyMOL
(http://pymol.sourceforge.net/).
Statistics
Statistical signiﬁcance was determined using a 2-tailed t test or
ANOVA where appropriate. P < 0.05 was considered signiﬁ-
cant (), P < 0.01 (); P < 0.001 () and P < 0.0001 ().
Abbreviations
ActD Actinomycin D
CDC7 cell division cycle 7
CDK2 cyclin-dependent kinase 2
Doxo Doxorubicine
IR irradiation
miR-192/215 micro RNAs 192 and/or 215
OAC origin of replication activation checkpoint
Rosco Roscovitine
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